References
- Council of the European Union. 2586th Council Meeting – Employment, social policy, health and consumer affairs. Available at: http://ue.eu.int/Newsroom/. Accessed May 5, 2010
- Atella V, Brady A, Catapano AL, et al. Bridging science and health policy in cardiovascular disease: focus on lipid management. Atherosclerosis Suppl 2010;10:3-21
- Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics. London: British Heart Foundation, 2005
- Moradi T, Allebeck P, Jacobsson A, et al. The burden of disease in Sweden measured with DALY. Neuropsychiatric diseases and cardiovascular diseases dominate. Läkartidningen 2006;103:137-41
- Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-9
- Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
- DeBacker G, Ambosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10
- Second Joint Task Force of the European and Other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-503
- Catapano AL, Reiner Z, De Backer G, et al. European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3-46
- Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359:2195-207
- Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost-effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ 2010;13:428-37
- Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of Rosuvastatin in the prevention of venous thromboembolism. New Engl J Med 2009;360:1-11
- Statistics Sweden (SCB). Life table (Livslangdstabell) 2003–2007. Available at: http://www.scb.se. Accessed January 11, 2010
- National Board of Health and Welfare (Socialstyrelsen). Statistics database, cause of death statistics (Socialstyrelsens statistisdatabas, dodsorsaksstatistik). Available at: http://www.socialstyrelsen.se. Accessed January 11, 2010
- Wilson, D'Agostino, Levy et al. Prediction of coronary heart disease using risk factor categories, Circulation 1998;97(18):1837-47
- Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007;11:1-160, iii–iv
- Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. New Engl J Med 2007;357:1477-86
- Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998;279:1458-62
- TLVs uppdrag angaende omregleringen av apoteksmarknaden, S2008/10720/HS. Available at: http://www.tlv.se. Accessed May 28, 2010
- Priser och ersättningar för Sydöstra Sjukvårdsregionen 2009, Beslut i Regionsjukvårdsnämnden 2008;12-09. Available at: http://www.lio.se/upload/16047/20081209Prislista2009.pdf. page 55. Accessed January 11, 2010
- Sigvant B, Henriksson M, Lundin F, et al. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? European Journal of Cardiovascular Prevention & Rehabilitation 2011;18:254-261
- KPP database. Available at: https://stat2.skl.se/kpp/index.htm. Accessed January 10, 2010
- Burstrom K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy 2006;76:359-70
- Scuffham PA, Kosa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-17
- Gold MR, Siegel JE, Russell LB, Weinstein MC, eds., Cost-effectiveness in Health and Medicine. Oxford University Press, New York, 2006
- Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
- Pignone M, Earnshaw S, Tice J, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-36
- Society of Cardiothoracic Surgeons of Great Britain and Ireland. UK cardiac surgical register. 2006. Available at: http://www.scts.org. Accessed January 11, 2010
- British Cardiovascular Intervention Society. PCI Database. 2005. Available at: http://www.bcis.org.uk. Accessed January 11, 2010